Research News Articles

In an amazing update for the ALS community, on September 29, 2022, the FDA voted to approve ALS drug AMX0035 for the treatment of ALS. This comes a year after Amylyx, a Massachusetts-based pharmaceutical company, submitted a New Drug Application (NDA) for AMX0035, a...

We’re excited to share another milestone in the search for better drug treatments for ALS. Amylyx announced today that the company will soon submit a New Drug Application (NDA) for AMX0035 to the FDA. The ALS Association has been closely following the development of...

In 2020, the ALS Association, in partnership with Massachusetts General Hospital, launched an innovative approach to research, the HEALEY ALS Platform Trial. In most clinical trials, a single drug is tested, and participants cannot be enrolled in more than one trial...

Muscle and Nerve has published the results of the open label extension study of AMX0035, a promising new drug therapy for people with ALS developed by Amylyx. The study showed that people who received the drug lived about 6.5 months longer than people who received the...